Nanjing Aidecheng Ningxin Pharmaceutical Research and Development

Nanjing Aidecheng Ningxin Pharmaceutical Research and Development is a specialized biotechnology firm based in Nanjing, China, focusing on the discovery and development of next-generation small molecule therapeutics. The company leverages advanced protein degradation technologies, specifically Proteolysis Targeting Chimeras (PROTACs) and molecular glues, to target previously undruggable proteins. As a key R&D subsidiary of the broader Adcent Pharmaceutical group, it provides both internal drug development and external contract research services to global partners. Its primary therapeutic focus is oncology, with a pipeline of candidates targeting hormone receptors and other key cancer drivers. The company is strategically located within the Nanjing Jiangbei New Area, a major hub for life science innovation in China.